NLS Pharmaceutics Ltd. -CW25NLSPWPreferred / convertible
13F holders, Q2 2025 (June 30)3holders
1new positions
1sold out
$0.02avg. 13F price*
At the end of Q2 2025, 3 institutions reported holding NLS Pharmaceutics Ltd. -CW25 (NLSPW) in their 13F filings, unchanged from Q1 2025. 1 opened new positions and 1 sold out. The largest holders were Clear Street LLC ($1K), Susquehanna International Group, LLP ($309) and Armistice Capital, LLC ($250).
- Company
- NLS Pharmaceutics Ltd. -CW25
- CUSIP
- H57830111
- Latest filing quarter
- Q3 2025
History
Number of 13F holders
Total Exit/New Position Q1 2025 → Q2 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $309 |
| Exits | 1 | $237 |
All 13F filers, Q1 2025 → Q2 2025: 16,453 shares bought and 18,381 shares sold, net −1,928 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 3 holders
| Clear Street LLC | — | Add +0.2% | 57,762 | $1K |
| Susquehanna International Group, LLP | — | New | 16,333 | $309 |
| Armistice Capital, LLC | — | No change | 12,500 | $250 |
"% of holder's portfolio" is NLSPW's weight in each manager's 13F, not the share of NLS Pharmaceutics Ltd. -CW25 the manager owns.